| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
22,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Impel Pharmaceuticals is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with unmet medical needs, with an initial focus on the Central Nervous System. Co. has launched Trudhesa for the acute treatment of migraine headaches with or without aura in adult patients. Co. is developing several product candidates, including INP105 for the acute treatment of agitation and aggression in patients with Autism Spectrum Disorder. Co.'s pipeline of proprietary product candidates also includes INP107 for the treatment of OFF episodes in Parkinson's Disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
575,000 |
575,000 |
575,000 |
| Total Sell Value |
$0 |
$74,131 |
$74,131 |
$74,131 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nelson Timothy S |
|
– • – |
2024-04-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(10,000) |
0 |
|
- |
|
| Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
– – • |
2023-12-19 |
4 |
S |
$0.08 |
$18,983 |
I/I |
(237,289) |
280,294 |
|
- |
|
| Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
– – • |
2023-12-18 |
4 |
S |
$0.11 |
$26,148 |
I/I |
(237,711) |
308,926 |
|
- |
|
| Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
– – • |
2023-12-15 |
4 |
S |
$0.29 |
$29,000 |
I/I |
(100,000) |
337,608 |
|
- |
|
| Leaman John Harold |
Chief Fin. & Business Officer |
• – – |
2022-12-31 |
4 |
D |
$3.75 |
$13,601 |
D/D |
(3,627) |
6,944 |
|
- |
|
| Leaman John Harold |
Chief Fin. & Business Officer |
• – – |
2022-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,571 |
10,571 |
|
- |
|
| Shrewsbury Stephen B |
Chief Medical Officer |
• – – |
2022-03-29 |
4 |
OE |
$1.97 |
$48,474 |
D/D |
24,606 |
97,990 |
|
- |
|
| Hoekman John |
Chief Scientific Officer |
• – – |
2021-12-22 |
4 |
OE |
$1.64 |
$32,800 |
D/D |
20,000 |
128,221 |
|
- |
|
| Shrewsbury Stephen B |
Chief Medical Officer |
• – – |
2021-09-21 |
4 |
OE |
$1.97 |
$199,720 |
D/D |
73,384 |
73,384 |
|
- |
|
| Adams Adrian |
COB, CEO and President |
• • – |
2021-08-18 |
4 |
B |
$13.81 |
$279,790 |
D/D |
20,000 |
20,000 |
2.81 |
- |
|
| Hoekman John |
Chief Scientific Officer |
• – – |
2021-04-27 |
4/A |
A |
$0.00 |
$0 |
D/D |
4,253 |
108,496 |
|
- |
|
| Parker H Stewart |
Director |
– • – |
2021-04-27 |
4 |
A |
$0.00 |
$3,659 |
D/D |
20,151 |
18,027 |
|
- |
|
| Parker H Stewart |
Director |
– • – |
2021-04-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,124) |
17,756 |
|
- |
|
| Roberts George R |
|
• • • |
2021-04-27 |
4 |
B |
$15.00 |
$16,500,000 |
I/I |
1,100,000 |
3,802,638 |
0.01 |
- |
|
| Roberts George R |
|
• • • |
2021-04-27 |
4 |
A |
$13.50 |
$1,602,612 |
I/I |
118,712 |
2,702,638 |
|
- |
|
| Roberts George R |
|
• • • |
2021-04-27 |
4 |
A |
$0.00 |
$0 |
I/I |
2,583,926 |
2,583,926 |
|
- |
|
| 5am Opportunities I (gp), Llc |
10% Owner |
– – • |
2021-04-27 |
4 |
B |
$15.00 |
$8,625,000 |
I/I |
575,000 |
575,000 |
1.5 |
- |
|
| 5am Opportunities I (gp), Llc |
10% Owner |
– – • |
2021-04-27 |
4 |
A |
$0.00 |
$1,369,670 |
I/I |
2,309,791 |
2,309,791 |
|
- |
|
| Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
– – • |
2021-04-27 |
4 |
B |
$15.00 |
$8,625,000 |
I/I |
575,000 |
349,674 |
1.5 |
- |
|
| Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
– – • |
2021-04-27 |
4 |
A |
$0.00 |
$1,369,656 |
I/I |
2,309,789 |
280,294 |
|
- |
|
| Kossow Jon Erik |
10% Owner |
– – • |
2021-04-27 |
4 |
B |
$15.00 |
$12,375,000 |
D/D |
825,000 |
3,077,198 |
2.45 |
- |
|
| Kossow Jon Erik |
10% Owner |
– – • |
2021-04-27 |
4 |
A |
$0.00 |
$1,335,515 |
D/D |
2,252,198 |
2,252,198 |
|
- |
|
| Hoekman John |
Chief Scientific Officer |
• – – |
2021-04-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(275) |
108,221 |
|
- |
|
| Hoekman John |
Chief Scientific Officer |
• – – |
2021-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,523 |
108,496 |
|
- |
|
| Adelman Robert J |
|
• • • |
2021-04-27 |
4 |
B |
$15.00 |
$6,750,000 |
D/D |
450,000 |
2,759,791 |
0.01 |
- |
|
27 Records found
|
|
Page 1 of 2 |
|
|
